With a new primary endpoint and the disappearance of a trial site, tiny Ritter claims a big clinical victory
Over the last few weeks, tiny LA-based Ritter Pharmaceuticals $RTTR has changed the primary endpoint and recalculated the data for its critical Phase IIb …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
